Prescription Drugs Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Product Type, Drug Type, Therapeutic Area, Route Of Administration, Distribution Channel, and Geography

Description

List of Tables

According to our new research study on "Prescription Drugs Market Forecast to 2031 -Global Analysis - by Product Type, Drug Type, Route Of Administration, Therapeutic Area, And Distribution Channel," the market is anticipated to grow from US$ 1,440.79 billion in 2024 and is projected to reach US$ 2,350.12 billion by 2031; it is expected to register a CAGR of 7.3% from 2025 to 2031. The prescription drugs market growth is attributed to the increasing prevalence of chronic disorders and development and adoption of innovative and specialty drugs.

Prescription drugs are medications that legally require a medical prescription from a licensed healthcare professional. They are regulated because they can have significant effects on the body, require monitoring for safety, or have potential for misuse.

The prescription drugs market in North America is segmented into the US, Canada, and Mexico. North America is likely to capture a significant share of the global market. One of the primary drivers is the region's aging population. As the baby boomer generation grows older, the prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer has increased, thereby boosting the demand for prescription medications.

Advancements in pharmaceutical research and biotechnology have also played a critical role. Innovations in drug development, including biologics and personalized medicine, have expanded treatment options, enhancing efficacy and safety. The introduction of novel therapies for previously untreatable conditions has further propelled market growth.

Another major contributor is the strong healthcare infrastructure in North America, supported by substantial investments in healthcare facilities, insurance coverage, and pharmaceutical distribution networks. The widespread availability of healthcare services and better patient awareness about disease management have increased prescription drug consumption. Additionally, regulatory support from agencies such as the US Food and Drug Administration (FDA) facilitates quicker approval processes for innovative drugs, enabling faster market entry. Furthermore, government initiatives aimed at expanding healthcare coverage, such as the Affordable Care Act in the US, have increased access to prescription drugs for a broader population.

Also, the rise in lifestyle-related diseases and increased prevalence of mental health disorders have created a sustained demand for therapeutic drugs. The COVID-19 pandemic also emphasized the importance of pharmaceutical interventions, accelerating investments in drug development and distribution.

In North America, the US holds a significant share of the prescription drugs market. Chronic conditions such as cancer, heart disease, and diabetes are contributing to the rising demand for prescription medications. Heart disease remains the leading cause of death in the US, with nearly one million Americans annually succumbing to cardiovascular disease (CVD). According to the American Heart Association, nearly half of all adults in the US have some type of CVD, and it is estimated that the number of adults suffering from heart failure is projected to increase by 2035. Over 130 million adults, i.e., 45.1% of the US population, are expected to report some form of CVD by 2035. This surge in CVD cases leads to a higher number of patients requiring long-term medication management, including statins, beta-blockers, anticoagulants, and antihypertensive drugs.

According to the American Cancer Society, in 2022, ~1.9 million new cases of cancer were diagnosed in the country, and it caused ~0.61 million deaths. With the increasing cases of cancer, the demand for innovative treatment options is rising. Therapeutic vaccines offer promising alternatives to traditional therapies. Provenge (sipuleucel-T), approved by the FDA in 2010, is the first therapeutic cancer vaccine to receive approval and prescribed medication for cancer treatment. Additionally, advancements in oncology, immunology, and gene therapies are expanding treatment options for various cancers and autoimmune diseases. Despite these advancements, prescription drug spending continues to rise. According to the American Society of Health-System Pharmacists, in 2024, Americans spent US$ 805.9 billion on prescription drugs, a 10.2% increase from the previous year. This increase is attributed to higher demand for these medications and the introduction of new, expensive treatments. Additionally, 79% of Americans believe that prescription drug prices are "unreasonable," while 70% consider reducing these costs to be their top healthcare priority. According to the Rand Corporation, on average, prescription drug prices in the US are 2.56 times higher than those in 32 other Organization for Economic Co-operation and Development (OECD) countries, with brand-name medications costing 3.44 times more. To address these costs, the Inflation Reduction Act (IRA), which aims to negotiate drug prices for Medicare, was introduced. In 2024, the US government finalized prices for the first ten drugs under the IRA 2022, marking a significant milestone. After months of negotiations with drug manufacturers, prices for medications such as Stelara and Jardiance have reduced by 38% to 79%. These changes are anticipated to save taxpayers US$6 billion by 2026 and provide US$1.5 billion in savings for patients.

While spending continues to rise, legislative efforts are underway to make medications more affordable for Americans. In May 2025, President Donald Trump signed an executive order titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients." Trump stated that the order aims to align the prices Americans and taxpayers pay for prescription drugs with those paid in comparable countries. The measure is expected to cut drug prices by at least 50% and is characterized as a more aggressive version of Trump's 2020 Most Favored Nation model.

Growth of Personalized and Precision Medicine to Provide Market Opportunities in Future

Personalized and precision medicine is experiencing growing technological advancements, increasing understanding of genomics, and rising adoption of personalized therapeutic approaches. Personalized medicine involves customizing healthcare based on individual genetic, environmental, and lifestyle factors, allowing for more effective and targeted treatments. The development of targeted cancer therapies such as trastuzumab (Herceptin) for HER2-positive breast cancer exemplifies how genetic profiling can identify patients who will benefit most from specific treatments, improving efficacy and reducing adverse effects. The increasing adoption of companion diagnostics is expected to integrate genetic testing into routine clinical practice, enhancing drug efficacy and safety.

Technological advancements such as artificial intelligence (AI) and big data analytics are accelerating discoveries in personalized medicine. AI-driven algorithms analyze vast datasets to predict individual responses to drugs, identify new therapeutic targets, and streamline drug development processes. For instance, companies such as Tempus are harnessing AI to tailor cancer treatments based on patients' genetic profiles, offering more precise and effective interventions. Therefore, technological innovations and increasing clinical adoption of more effective, safer, and patient-centric therapies, transforming healthcare delivery and outcomes globally, are expected to contribute to the market growth in coming years.

The US Food and Drug Administration, National Cancer Institute, European Medicines Agency, Central Drugs Standard Control Organization, and Our World in data are among the primary and secondary sources referred to while preparing the prescription drugs market report.

Product Code: TIPRE00040966

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Analyst Market Outlook

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
3.3 Assumptions and Limitations

4. Prescription Drugs Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Prescription Drugs Market - Key Market Dynamics

5.1 Prescription Drugs Market - Key Market Dynamics
5.2 Market Drivers:
- 5.2.1 Increasing Prevalence of Chronic Disorders
- 5.2.2 Development and Adoption of Innovative and Specialty Drugs
5.3 Market Restraints
- 5.3.1 High Drug Prices and Affordability Issues
5.4 Market Opportunities
- 5.4.1 Strategic Initiatives by Market Players
5.5 Future Trends
- 5.5.1 Growth of Personalized and Precision Medicine
5.6 Impact of Drivers and Restraints:

6. Prescription Drugs Market - Global Market Analysis

6.1 Prescription Drugs Market Revenue (US$ Billion), 2021-2031
6.2 Prescription Drugs Market Forecast Analysis

7. Prescription Drugs Market Analysis - by Product Type

7.1 Branded
- 7.1.1 Overview
- 7.1.2 Branded: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
7.2 Generics
- 7.2.1 Overview
- 7.2.2 Generics: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)

8. Prescription Drugs Market Analysis - by Drug Type

8.1 Small Molecule
- 8.1.1 Overview
- 8.1.2 Small Molecule: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
8.2 Biologics and Biosimilar
- 8.2.1 Overview
- 8.2.2 Biologics and Biosimilar: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)

9. Prescription Drugs Market Analysis - by Therapeutic Area

9.1 Oncology
- 9.1.1 Overview
- 9.1.2 Oncology: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
9.2 Cardiovascular Diseases
- 9.2.1 Overview
- 9.2.2 Cardiovascular Diseases: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
9.3 Neurological Diseases
- 9.3.1 Overview
- 9.3.2 Neurological Diseases: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
9.4 Metabolic Diseases
- 9.4.1 Overview
- 9.4.2 Metabolic Diseases: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
9.5 Respiratory Diseases
- 9.5.1 Overview
- 9.5.2 Respiratory Diseases: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
9.6 Immunology
- 9.6.1 Overview
- 9.6.2 Immunology: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
9.7 Others
- 9.7.1 Overview
- 9.7.2 Others: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)

10. Prescription Drugs Market Analysis - by Route Of Administration

10.1 Oral
- 10.1.1 Overview
- 10.1.2 Oral: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
10.2 Injectable
- 10.2.1 Overview
- 10.2.2 Injectable: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
10.3 Topical
- 10.3.1 Overview
- 10.3.2 Topical: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
10.4 Others
- 10.4.1 Overview
- 10.4.2 Others: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)

11. Prescription Drugs Market Analysis - by Distribution Channel

11.1 Hospital Pharmacies
- 11.1.1 Overview
- 11.1.2 Hospital Pharmacies: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
11.2 Retail Pharmacies
- 11.2.1 Overview
- 11.2.2 Retail Pharmacies: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)
11.3 Online Pharmacies
- 11.3.1 Overview
- 11.3.2 Online Pharmacies: Prescription Drugs Market - Revenue and Forecast to 2031 (US$ Billion)

12. Prescription Drugs Market - Geographical Analysis

12.1 North America
- 12.1.1 North America Prescription Drugs Market Overview
- 12.1.2 North America: Prescription Drugs Market - Revenue, 2021-2031 (US$ Billion)
  - 12.1.2.1 North America: Prescription Drugs Market - Revenue and Forecast Analysis - by Product Type
  - 12.1.2.2 North America: Prescription Drugs Market - Revenue and Forecast Analysis - by Drug Type
  - 12.1.2.3 North America: Prescription Drugs Market - Revenue and Forecast Analysis - by Therapeutic Area
  - 12.1.2.4 North America: Prescription Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
  - 12.1.2.5 North America: Prescription Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.1.3 North America: Prescription Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.1.3.1 United States: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.1.3.1.1 United States: Prescription Drugs Market Breakdown, by Product Type
    - 12.1.3.1.2 United States: Prescription Drugs Market Breakdown, by Drug Type
    - 12.1.3.1.3 United States: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.1.3.1.4 United States: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.1.3.1.5 United States: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.1.3.2 Canada: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.1.3.2.1 Canada: Prescription Drugs Market Breakdown, by Product Type
    - 12.1.3.2.2 Canada: Prescription Drugs Market Breakdown, by Drug Type
    - 12.1.3.2.3 Canada: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.1.3.2.4 Canada: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.1.3.2.5 Canada: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.1.3.3 Mexico: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.1.3.3.1 Mexico: Prescription Drugs Market Breakdown, by Product Type
    - 12.1.3.3.2 Mexico: Prescription Drugs Market Breakdown, by Drug Type
    - 12.1.3.3.3 Mexico: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.1.3.3.4 Mexico: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.1.3.3.5 Mexico: Prescription Drugs Market Breakdown, by Distribution Channel
12.2 Europe
- 12.2.1 Europe Prescription Drugs Market Overview
- 12.2.2 Europe: Prescription Drugs Market - Revenue, 2021-2031 (US$ Billion)
  - 12.2.2.1 Europe: Prescription Drugs Market - Revenue and Forecast Analysis - by Product Type
  - 12.2.2.2 Europe: Prescription Drugs Market - Revenue and Forecast Analysis - by Drug Type
  - 12.2.2.3 Europe: Prescription Drugs Market - Revenue and Forecast Analysis - by Therapeutic Area
  - 12.2.2.4 Europe: Prescription Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
  - 12.2.2.5 Europe: Prescription Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.2.3 Europe: Prescription Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.2.3.1 Germany: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.2.3.1.1 Germany: Prescription Drugs Market Breakdown, by Product Type
    - 12.2.3.1.2 Germany: Prescription Drugs Market Breakdown, by Drug Type
    - 12.2.3.1.3 Germany: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.2.3.1.4 Germany: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.2.3.1.5 Germany: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.2.3.2 United Kingdom: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.2.3.2.1 United Kingdom: Prescription Drugs Market Breakdown, by Product Type
    - 12.2.3.2.2 United Kingdom: Prescription Drugs Market Breakdown, by Drug Type
    - 12.2.3.2.3 United Kingdom: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.2.3.2.4 United Kingdom: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.2.3.2.5 United Kingdom: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.2.3.3 France: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.2.3.3.1 France: Prescription Drugs Market Breakdown, by Product Type
    - 12.2.3.3.2 France: Prescription Drugs Market Breakdown, by Drug Type
    - 12.2.3.3.3 France: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.2.3.3.4 France: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.2.3.3.5 France: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.2.3.4 Italy: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.2.3.4.1 Italy: Prescription Drugs Market Breakdown, by Product Type
    - 12.2.3.4.2 Italy: Prescription Drugs Market Breakdown, by Drug Type
    - 12.2.3.4.3 Italy: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.2.3.4.4 Italy: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.2.3.4.5 Italy: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.2.3.5 Spain: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.2.3.5.1 Spain: Prescription Drugs Market Breakdown, by Product Type
    - 12.2.3.5.2 Spain: Prescription Drugs Market Breakdown, by Drug Type
    - 12.2.3.5.3 Spain: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.2.3.5.4 Spain: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.2.3.5.5 Spain: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.2.3.6 Rest of Europe: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.2.3.6.1 Rest of Europe: Prescription Drugs Market Breakdown, by Product Type
    - 12.2.3.6.2 Rest of Europe: Prescription Drugs Market Breakdown, by Drug Type
    - 12.2.3.6.3 Rest of Europe: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.2.3.6.4 Rest of Europe: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.2.3.6.5 Rest of Europe: Prescription Drugs Market Breakdown, by Distribution Channel
12.3 Asia Pacific
- 12.3.1 Asia Pacific Prescription Drugs Market Overview
- 12.3.2 Asia Pacific: Prescription Drugs Market - Revenue, 2021-2031 (US$ Billion)
  - 12.3.2.1 Asia Pacific: Prescription Drugs Market - Revenue and Forecast Analysis - by Product Type
  - 12.3.2.2 Asia Pacific: Prescription Drugs Market - Revenue and Forecast Analysis - by Drug Type
  - 12.3.2.3 Asia Pacific: Prescription Drugs Market - Revenue and Forecast Analysis - by Therapeutic Area
  - 12.3.2.4 Asia Pacific: Prescription Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
  - 12.3.2.5 Asia Pacific: Prescription Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.3.3 Asia Pacific: Prescription Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.3.3.1 China: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.3.3.1.1 China: Prescription Drugs Market Breakdown, by Product Type
    - 12.3.3.1.2 China: Prescription Drugs Market Breakdown, by Drug Type
    - 12.3.3.1.3 China: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.3.3.1.4 China: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.3.3.1.5 China: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.3.3.2 Japan: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.3.3.2.1 Japan: Prescription Drugs Market Breakdown, by Product Type
    - 12.3.3.2.2 Japan: Prescription Drugs Market Breakdown, by Drug Type
    - 12.3.3.2.3 Japan: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.3.3.2.4 Japan: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.3.3.2.5 Japan: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.3.3.3 India: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.3.3.3.1 India: Prescription Drugs Market Breakdown, by Product Type
    - 12.3.3.3.2 India: Prescription Drugs Market Breakdown, by Drug Type
    - 12.3.3.3.3 India: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.3.3.3.4 India: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.3.3.3.5 India: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.3.3.4 Australia: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.3.3.4.1 Australia: Prescription Drugs Market Breakdown, by Product Type
    - 12.3.3.4.2 Australia: Prescription Drugs Market Breakdown, by Drug Type
    - 12.3.3.4.3 Australia: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.3.3.4.4 Australia: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.3.3.4.5 Australia: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.3.3.5 South Korea: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.3.3.5.1 South Korea: Prescription Drugs Market Breakdown, by Product Type
    - 12.3.3.5.2 South Korea: Prescription Drugs Market Breakdown, by Drug Type
    - 12.3.3.5.3 South Korea: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.3.3.5.4 South Korea: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.3.3.5.5 South Korea: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.3.3.6 Rest of APAC: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.3.3.6.1 Rest of APAC: Prescription Drugs Market Breakdown, by Product Type
    - 12.3.3.6.2 Rest of APAC: Prescription Drugs Market Breakdown, by Drug Type
    - 12.3.3.6.3 Rest of APAC: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.3.3.6.4 Rest of APAC: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.3.3.6.5 Rest of APAC: Prescription Drugs Market Breakdown, by Distribution Channel
12.4 Middle East and Africa
- 12.4.1 Middle East and Africa Prescription Drugs Market Overview
- 12.4.2 Middle East and Africa: Prescription Drugs Market - Revenue, 2021-2031 (US$ Billion)
  - 12.4.2.1 Middle East and Africa: Prescription Drugs Market - Revenue and Forecast Analysis - by Product Type
  - 12.4.2.2 Middle East and Africa: Prescription Drugs Market - Revenue and Forecast Analysis - by Drug Type
  - 12.4.2.3 Middle East and Africa: Prescription Drugs Market - Revenue and Forecast Analysis - by Therapeutic Area
  - 12.4.2.4 Middle East and Africa: Prescription Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
  - 12.4.2.5 Middle East and Africa: Prescription Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.4.3 Middle East and Africa: Prescription Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.4.3.1 Saudi Arabia: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.4.3.1.1 Saudi Arabia: Prescription Drugs Market Breakdown, by Product Type
    - 12.4.3.1.2 Saudi Arabia: Prescription Drugs Market Breakdown, by Drug Type
    - 12.4.3.1.3 Saudi Arabia: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.4.3.1.4 Saudi Arabia: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.4.3.1.5 Saudi Arabia: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.4.3.2 South Africa: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.4.3.2.1 South Africa: Prescription Drugs Market Breakdown, by Product Type
    - 12.4.3.2.2 South Africa: Prescription Drugs Market Breakdown, by Drug Type
    - 12.4.3.2.3 South Africa: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.4.3.2.4 South Africa: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.4.3.2.5 South Africa: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.4.3.3 United Arab Emirates: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.4.3.3.1 United Arab Emirates: Prescription Drugs Market Breakdown, by Product Type
    - 12.4.3.3.2 United Arab Emirates: Prescription Drugs Market Breakdown, by Drug Type
    - 12.4.3.3.3 United Arab Emirates: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.4.3.3.4 United Arab Emirates: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.4.3.3.5 United Arab Emirates: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.4.3.4 Rest of Middle East and Africa: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.4.3.4.1 Rest of Middle East and Africa: Prescription Drugs Market Breakdown, by Product Type
    - 12.4.3.4.2 Rest of Middle East and Africa: Prescription Drugs Market Breakdown, by Drug Type
    - 12.4.3.4.3 Rest of Middle East and Africa: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.4.3.4.4 Rest of Middle East and Africa: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.4.3.4.5 Rest of Middle East and Africa: Prescription Drugs Market Breakdown, by Distribution Channel
12.5 South and Central America
- 12.5.1 South and Central America Prescription Drugs Market Overview
- 12.5.2 South and Central America: Prescription Drugs Market - Revenue, 2021-2031 (US$ Billion)
  - 12.5.2.1 South and Central America: Prescription Drugs Market - Revenue and Forecast Analysis - by Product Type
  - 12.5.2.2 South and Central America: Prescription Drugs Market - Revenue and Forecast Analysis - by Drug Type
  - 12.5.2.3 South and Central America: Prescription Drugs Market - Revenue and Forecast Analysis - by Therapeutic Area
  - 12.5.2.4 South and Central America: Prescription Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
  - 12.5.2.5 South and Central America: Prescription Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.5.3 South and Central America: Prescription Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.5.3.1 Brazil: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.5.3.1.1 Brazil: Prescription Drugs Market Breakdown, by Product Type
    - 12.5.3.1.2 Brazil: Prescription Drugs Market Breakdown, by Drug Type
    - 12.5.3.1.3 Brazil: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.5.3.1.4 Brazil: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.5.3.1.5 Brazil: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.5.3.2 Argentina: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.5.3.2.1 Argentina: Prescription Drugs Market Breakdown, by Product Type
    - 12.5.3.2.2 Argentina: Prescription Drugs Market Breakdown, by Drug Type
    - 12.5.3.2.3 Argentina: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.5.3.2.4 Argentina: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.5.3.2.5 Argentina: Prescription Drugs Market Breakdown, by Distribution Channel
  - 12.5.3.3 Rest of South and Central America: Prescription Drugs Market - Revenue and Forecast, 2021-2031 (US$ Billion)
    - 12.5.3.3.1 Rest of South and Central America: Prescription Drugs Market Breakdown, by Product Type
    - 12.5.3.3.2 Rest of South and Central America: Prescription Drugs Market Breakdown, by Drug Type
    - 12.5.3.3.3 Rest of South and Central America: Prescription Drugs Market Breakdown, by Therapeutic Area
    - 12.5.3.3.4 Rest of South and Central America: Prescription Drugs Market Breakdown, by Route Of Administration
    - 12.5.3.3.5 Rest of South and Central America: Prescription Drugs Market Breakdown, by Distribution Channel

13. Competitive Landscape

13.1 Heat Map Analysis by Key Players
13.2 Company Positioning & Concentration

14. Industry Landscape

14.1 Overview
14.2 Growth Strategies in the Prescription Drugs Market
14.3 Organic Growth Strategies
- 14.3.1 Overview
14.4 Inorganic Growth Strategies
- 14.4.1 Overview

15. Company Profiles

15.1 Johnson & Johnson
- 15.1.1 Key Facts
- 15.1.2 Business Description
- 15.1.3 Products and Services
- 15.1.4 Financial Overview
- 15.1.5 SWOT Analysis
- 15.1.6 Key Developments
15.2 Pfizer Inc
- 15.2.1 Key Facts
- 15.2.2 Business Description
- 15.2.3 Products and Services
- 15.2.4 Financial Overview
- 15.2.5 SWOT Analysis
- 15.2.6 Key Developments
15.3 Merck & Co Inc
- 15.3.1 Key Facts
- 15.3.2 Business Description
- 15.3.3 Products and Services
- 15.3.4 Financial Overview
- 15.3.5 SWOT Analysis
- 15.3.6 Key Developments
15.4 Eli Lilly and Co
- 15.4.1 Key Facts
- 15.4.2 Business Description
- 15.4.3 Products and Services
- 15.4.4 Financial Overview
- 15.4.5 SWOT Analysis
- 15.4.6 Key Developments
15.5 ESTEVE
- 15.5.1 Key Facts
- 15.5.2 Business Description
- 15.5.3 Products and Services
- 15.5.4 Financial Overview
- 15.5.5 SWOT Analysis
- 15.5.6 Key Developments
15.6 AstraZeneca Plc
- 15.6.1 Key Facts
- 15.6.2 Business Description
- 15.6.3 Products and Services
- 15.6.4 Financial Overview
- 15.6.5 SWOT Analysis
- 15.6.6 Key Developments
15.7 Sanofi SA
- 15.7.1 Key Facts
- 15.7.2 Business Description
- 15.7.3 Products and Services
- 15.7.4 Financial Overview
- 15.7.5 SWOT Analysis
- 15.7.6 Key Developments
15.8 GSK Plc
- 15.8.1 Key Facts
- 15.8.2 Business Description
- 15.8.3 Products and Services
- 15.8.4 Financial Overview
- 15.8.5 SWOT Analysis
- 15.8.6 Key Developments
15.9 F. Hoffmann-La Roche Ltd
- 15.9.1 Key Facts
- 15.9.2 Business Description
- 15.9.3 Products and Services
- 15.9.4 Financial Overview
- 15.9.5 SWOT Analysis
- 15.9.6 Key Developments
15.10 Novartis AG
- 15.10.1 Key Facts
- 15.10.2 Business Description
- 15.10.3 Products and Services
- 15.10.4 Financial Overview
- 15.10.5 SWOT Analysis
- 15.10.6 Key Developments
15.11 AbbVie Inc
- 15.11.1 Key Facts
- 15.11.2 Business Description
- 15.11.3 Products and Services
- 15.11.4 Financial Overview
- 15.11.5 SWOT Analysis
- 15.11.6 Key Developments
15.12 Teva Pharmaceutical Industries Ltd
- 15.12.1 Key Facts
- 15.12.2 Business Description
- 15.12.3 Products and Services
- 15.12.4 Financial Overview
- 15.12.5 SWOT Analysis
- 15.12.6 Key Developments

16. Appendix

16.1 About The Insight Partners
16.2 Glossary of Terms